abcnews.go.com
🌐 85% Global Worthiness
J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.
J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.
Progress
36% Bias Score
Good Health and Well-being